Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595550 | 0.89 | DRD2 (0.55) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL13061367 | 0.80 | NCF1 (0.59) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL16463118 | 0.76 | ADRA2C (0.43) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL188681 | 0.74 | NCF1 (0.39) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL3598987 | 0.74 | ALDH1A1 (0.43) | DRD2DRD3DRD4MAPTGAA | |
| SCHEMBL4173801 | 0.73 | DRD2 (0.45) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL3584990 | 0.73 | ALDH1A1 (0.47) | DRD2DRD3NCF1ADRA2CKDM4E | |
| SCHEMBL3589113 | 0.73 | DRD2 (0.50) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL188661 | 0.73 | NCF1 (0.41) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL3591857 | 0.73 | HRH4 (0.37) | DRD2DRD3HTR1ADRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | DRD2 4782/4885DRD3 4637/4885HTR1A 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.